IS6560A - Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni - Google Patents

Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni

Info

Publication number
IS6560A
IS6560A IS6560A IS6560A IS6560A IS 6560 A IS6560 A IS 6560A IS 6560 A IS6560 A IS 6560A IS 6560 A IS6560 A IS 6560A IS 6560 A IS6560 A IS 6560A
Authority
IS
Iceland
Prior art keywords
pain
migraine
acute
treatment
pharmaceutical composition
Prior art date
Application number
IS6560A
Other languages
English (en)
Inventor
Wadsworth Coe Jotham
Patrick Harrigan Edmund
Thomas O'neill Brian
Bradley Sands Steven
Jacob Watsky Eric
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6560A publication Critical patent/IS6560A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IS6560A 2000-04-07 2002-09-20 Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni IS6560A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19573800P 2000-04-07 2000-04-07
PCT/IB2001/000391 WO2001076576A2 (en) 2000-04-07 2001-03-16 A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines

Publications (1)

Publication Number Publication Date
IS6560A true IS6560A (is) 2002-09-20

Family

ID=22722582

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6560A IS6560A (is) 2000-04-07 2002-09-20 Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni

Country Status (35)

Country Link
US (2) US20010036943A1 (is)
EP (1) EP1272218B1 (is)
JP (1) JP2003530345A (is)
KR (1) KR20030040201A (is)
CN (1) CN1468111A (is)
AP (1) AP2002002642A0 (is)
AR (1) AR027773A1 (is)
AT (1) ATE291438T1 (is)
AU (1) AU3768001A (is)
BG (1) BG107138A (is)
BR (1) BR0109837A (is)
CA (1) CA2405142A1 (is)
CR (1) CR6767A (is)
CZ (1) CZ20023214A3 (is)
DE (1) DE60109589T2 (is)
EA (1) EA004930B1 (is)
EE (1) EE200200579A (is)
ES (1) ES2236185T3 (is)
GT (1) GT200100055A (is)
HU (1) HUP0301822A3 (is)
IL (1) IL152076A0 (is)
IS (1) IS6560A (is)
MA (1) MA26889A1 (is)
MX (1) MXPA02009817A (is)
NO (1) NO20024734D0 (is)
OA (1) OA12241A (is)
PA (1) PA8515001A1 (is)
PE (1) PE20011307A1 (is)
PL (1) PL365957A1 (is)
SK (1) SK13952002A3 (is)
SV (1) SV2002000377A (is)
TN (1) TNSN01053A1 (is)
WO (1) WO2001076576A2 (is)
YU (1) YU74602A (is)
ZA (1) ZA200207996B (is)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6545057B2 (en) * 2000-09-26 2003-04-08 The Brigham And Women's Hospital Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
US7074961B2 (en) 2000-09-26 2006-07-11 The Brigham And Women's Hospital, Inc. Antidepressants and their analogues as long-acting local anesthetics and analgesics
KR100551183B1 (ko) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법
DK1395289T3 (da) * 2001-06-07 2011-03-28 Christine Dr Sang Behandling af neuropatisk smerte med en N-methyl-D-aspartat- (NMDA-)receptorantagonist
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040138239A1 (en) * 2001-08-23 2004-07-15 Bruce Frome Compositions and methods for targeting cerebral circulation and treatment of headache
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
BR0213612A (pt) 2001-10-02 2004-08-24 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1442037A1 (en) 2001-11-09 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
WO2003049753A1 (en) * 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
KR20040085151A (ko) * 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
WO2003066040A1 (fr) * 2002-02-05 2003-08-14 Ajinomoto Co.,Inc. Compositions medicinales contenant une gabapentine ou une pregabaline et antagoniste a canal de calcium de type n
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
BR0307714A (pt) 2002-02-15 2005-02-09 Upjohn Co Benzoilamidas substituìdas com azabiciclo e tioamidas para tratamento de distúrbios relacionados ao cns
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
AU2003217275A1 (en) 2002-02-19 2003-09-09 Pharmacia And Upjohn Company Azabicyclic compounds for the treatment of disease
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US20040014681A1 (en) * 2002-05-14 2004-01-22 Ralph Ryback Method for treating dermatoses and tissue damage
WO2003097043A1 (en) * 2002-05-15 2003-11-27 Abbott Laboratories Treatment of neuropathic pain
JP4615309B2 (ja) 2002-05-17 2011-01-19 オセラ・ホールディング・インコーポレイテッド 白内障および他の眼球疾患の進行の改善
JP2006509735A (ja) * 2002-10-17 2006-03-23 ノバルティス アクチエンゲゼルシャフト オクスカルバゼピンまたはその誘導体およびｃｏｘ２インヒビターからなる疼痛処置用医薬組成物
ATE547424T1 (de) 2002-12-02 2012-03-15 Xenome Ltd Chi-conotoxinpeptide mit einer n-terminalen pyroglutaminsäure
WO2004050688A1 (en) 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004056363A2 (en) 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
JP2007528352A (ja) * 2003-03-06 2007-10-11 ボツリヌム・トクシン・リサーチ・アソシエイツ・インコーポレイテッド 洞炎に関連する慢性の顔面痛および頭痛のボツリヌス毒素での治療
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004230915B2 (en) * 2003-04-08 2008-08-07 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US20050004219A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Pump systems including injectable gabapentin compositions
US20050004221A1 (en) * 2003-07-01 2005-01-06 Medtronic, Inc. Intrathecal gabapentin compositions
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005032556A1 (en) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Method for reducing pain
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
US20050090549A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of pain
AU2004291082A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
HU230403B1 (hu) * 2003-12-19 2016-04-28 Pál Kocsis Nátrium csatorna blokkoló és szerotonin újrafelvétel gátló tartalmú gyógyszerkészítmény
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1765300A2 (en) * 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2005299748B2 (en) * 2004-10-21 2009-04-09 Tgel Bio Co., Ltd In situ controlled release drug delivery system
US20080176873A1 (en) * 2004-11-10 2008-07-24 Trinity Laboratories, Inc. Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria
MX2007006253A (es) * 2004-11-24 2007-10-18 Anesiva Inc Formulacion de gel de capsaicinoide y usos para esta.
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2006127184A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
JP2007308403A (ja) * 2006-05-17 2007-11-29 Kenji Yoshida 皮膚外用剤
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
JP5192485B2 (ja) * 2006-07-17 2013-05-08 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 向精神性薬物またはｇａｂａアゴニストと有機酸とを含むコンジュゲート、ならびに疼痛および他のｃｎｓ障害を治療するためのそれらの使用
WO2008020651A1 (fr) * 2006-08-17 2008-02-21 Kyushu University, National University Corporation antagoniste de récepteur P2X4
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
EP2081562B1 (en) * 2006-09-20 2016-02-24 The Board of Regents of The University of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
US20100048605A1 (en) * 2006-12-11 2010-02-25 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
US20100312073A1 (en) * 2008-01-31 2010-12-09 David Yarnitsky Method of predicting pain medication efficacy
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
EP2756756B1 (en) 2008-04-28 2016-01-06 Zogenix, Inc. Novel formulations for treatment of migraine
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
PL2582366T3 (pl) 2010-06-15 2016-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna do leczenia bólu
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
MX2013009544A (es) * 2011-02-18 2013-09-26 Nestec Sa Metodos y composiciones para tratar, reducir o prevenir daño al sistema nervioso de animales.
ES2387973B1 (es) * 2011-03-18 2013-10-01 Dr Healthcare España, S. L. Composiciones tópicas que contienen diaminooxidasa para el tratamiento o la prevención de enfermedades asociadas a un nivel de histamina elevada que comportan un aumento del dolor.
US8580850B2 (en) 2011-08-11 2013-11-12 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use
BR112015003393A2 (pt) * 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
CN104758933A (zh) * 2014-10-29 2015-07-08 吴鑫欣 治疗神经卡压、神经瘤疼痛的药物和给药系统
CA3057304A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018183320A1 (en) * 2017-03-31 2018-10-04 Depco, Inc. Therapeutic putty having analgesics and/or counterirritants
EP3609480A4 (en) * 2017-04-12 2021-05-19 Synergistic Therapeutics, LLC THERAPEUTIC LOTION AGAINST NEUROPATHIC PAIN
KR101944113B1 (ko) 2017-09-28 2019-01-30 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
KR102156627B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 보스웰리아 추출물 및 산자나무 추출물을 포함하는 급성 안면통증 예방 및 개선용 조성물
KR102156438B1 (ko) 2018-12-20 2020-09-16 동의대학교 산학협력단 급성 안면통증 예방 및 개선용 조성물
CN115054601B (zh) * 2022-03-21 2024-04-26 中山大学附属第三医院 一种可注射的缓释镇痛复合物及其制备方法、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE326468T1 (de) * 1996-10-30 2006-06-15 Pfizer Pyridon-kondensierte azabicyclische- oder cytisin-derivate, ihre herstellung und verwendung in der suchttherapie
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
PT1076650E (pt) * 1998-04-29 2004-05-31 Pfizer Prod Inc Compostos azapoliciclicos fundidos com arilo
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
KR20030040201A (ko) 2003-05-22
CA2405142A1 (en) 2001-10-18
IL152076A0 (en) 2003-05-29
TNSN01053A1 (fr) 2005-11-10
OA12241A (en) 2004-01-27
HUP0301822A3 (en) 2005-06-28
CZ20023214A3 (cs) 2003-11-12
CN1468111A (zh) 2004-01-14
AU3768001A (en) 2001-10-23
AR027773A1 (es) 2003-04-09
ATE291438T1 (de) 2005-04-15
JP2003530345A (ja) 2003-10-14
EP1272218B1 (en) 2005-03-23
NO20024734D0 (no) 2002-10-02
US20010036943A1 (en) 2001-11-01
BG107138A (en) 2003-05-30
MXPA02009817A (es) 2003-03-27
US20030133951A1 (en) 2003-07-17
PL365957A1 (en) 2005-01-24
ES2236185T3 (es) 2005-07-16
HUP0301822A2 (hu) 2003-11-28
PE20011307A1 (es) 2001-12-28
EA004930B1 (ru) 2004-10-28
YU74602A (sh) 2006-05-25
BR0109837A (pt) 2003-01-21
CR6767A (es) 2004-06-09
DE60109589D1 (de) 2005-04-28
MA26889A1 (fr) 2004-12-20
EP1272218A2 (en) 2003-01-08
EA200200910A1 (ru) 2003-02-27
GT200100055A (es) 2001-12-31
PA8515001A1 (es) 2002-02-21
DE60109589T2 (de) 2005-09-01
SV2002000377A (es) 2002-07-03
ZA200207996B (en) 2003-10-20
EE200200579A (et) 2004-06-15
WO2001076576A2 (en) 2001-10-18
SK13952002A3 (sk) 2003-12-02
WO2001076576A3 (en) 2002-06-20
AP2002002642A0 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DK1339406T3 (da) Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DE69922631D1 (de) Superkritische behandlung von aktivkohle
DE29602789U1 (de) Liege, Decke o.dgl. zur therapeutischen Behandlung von Lebewesen
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
NO20005179D0 (no) Medikament behandling
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
MXPA03004303A (es) DERIVADOS SUSTITUIDOS DE ACIDO AMINO-FURAN-2-IL-ACETICO Y ACIDO AMINO-TIEN-2-IL-ACETICO Y SU USO PARA EL TRATAMIENTO DE MIGRAnA Y DOLOR.
PT1286986E (pt) Derivados de quinolil-piperidin-4-ilideno-metil-benzamida para o tratamento da dor
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
NO20031108L (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
PT1305307E (pt) Derivados de indole eficazes no tratamento de doencas do sistema nervoso central
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
NO20022990L (no) Fremgangsmåte og sammensetning for behandling av smerte
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
PT1244662E (pt) Derivado de piridazinoquinolina e metodo para o tratamento da dor
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri